Compare RCAT & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCAT | OGN |
|---|---|---|
| Founded | 2002 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.5B |
| IPO Year | 2017 | 2020 |
| Metric | RCAT | OGN |
|---|---|---|
| Price | $12.55 | $8.55 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 4 |
| Target Price | ★ $20.00 | $11.75 |
| AVG Volume (30 Days) | ★ 14.3M | 5.6M |
| Earning Date | 05-13-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 0.94% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.72 |
| Revenue | $17,836,382.00 | ★ $6,216,000,000.00 |
| Revenue This Year | $271.60 | $0.42 |
| Revenue Next Year | $41.21 | $1.67 |
| P/E Ratio | ★ N/A | $11.83 |
| Revenue Growth | ★ 79.95 | N/A |
| 52 Week Low | $4.60 | $5.69 |
| 52 Week High | $18.78 | $13.25 |
| Indicator | RCAT | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 46.03 | 69.50 |
| Support Level | $10.52 | $8.32 |
| Resistance Level | $13.22 | $9.79 |
| Average True Range (ATR) | 1.36 | 0.48 |
| MACD | -0.14 | 0.36 |
| Stochastic Oscillator | 22.95 | 86.66 |
Red Cat Holdings Inc is a drone technology company integrating robotic hardware and software for military, government, and commercial operations. Red Cat's suite of solutions includes the Arachnid family of ISR and precision strike drones, which includes the Black Widow, a small unmanned ISR system; and WEB (Warfighter Electronic Bridge) GCS, designed to command and control an entire drone family of systems for military operations. Its other offerings include Edge 130 Blue drone systems, Trichon, a fixed-wing VTOL for extended endurance and range, and FANG FPV drones optimized for military operations with precision strike capabilities.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.